Alamar Biosciences is building a next-generation proteomic platform for plasma and liquid protein detection. Proteins present in blood samples have potential use as biomarkers for early detection and prevention of diseases, but many of these proteins are currently outside the detectable range due to their low abundance. Alamar is creating the most sensitive proteomic liquid biopsy platform that can profile thousands of proteins from microliters of blood. The fully automated platform achieves unparalleled sensitivity by using Alamar’s two breakthrough technologies: NULISA and Attobody. Together, Alamar’s platform can achieve single-digit attomolar detection, surpassing currently available technology and providing the potential to transform healthcare.